# Signals Article: Putative Target P04049 for Hypertrophic Cardiomyopathy
Background
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by the thickening of the heart muscle, which can lead to heart failure and sudden cardiac death. It is the most common genetic heart disease and presents significant challenges in diagnosis and management. Identifying novel molecular targets could lead to improved therapeutic strategies for managing HCM.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P04049 was identified as a putative target for HCM. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200194397, GDS:200194394, GDS:200143786, GDS:200148602, and GDS:200108200. Although P04049 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P04049 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P04049's potential as a target for HCM. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P04049 as a target for HCM, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of HCM. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P04049. If validated, assessing the druggability of P04049 via DGIdb and ChEMBL will be crucial for potential therapeutic development.